• Betty Matimba Bumba
• Paranjeet Kaur

Breast cancer is the most common cancer affecting women world-wide. Because breast cancer is the most common malignancy in women it's for this reason the review provides information on the recent developments of the drug targets in the management of breast cancer. Over the past decades various advancements have been made in the discovery of new drugs for treating breast cancer and this is because of the improved understanding of the biologic heterogeneity of breast cancer which has also allowed the development of more effective approaches to treat breast cancer. Approximately 70% of breast cancers are estrogen receptor positive. Aromatase and Tamoxifen have been used for endocrine therapy and have improved breast cancer survival but a large number of people experience occurrence of the disease either during or near the completion of endocrine therapy.1 However introduction of new drugs targeting molecular pathway involved in endocrine resistance. The use of combination of endocrine therapy with mammalian target of Rapamycin antagonists with the introduction of cyclin dependent kinase 4/6 inhibitors has significantly improved the response to endocrine therapy.2 Moving forward HER 2 target immunotherapy consists of monoclonal antibodies such Pertuzumab and Trastuzumab and bispecific antibodies and activated T-cells armed with anti-HER 2 positive metastatic breast cancer.3 This combined application of the drugs mentioned above plus paclitaxel are a standard therapy for HER 2 positive breast cancer. Although much needs to be done in improving outcomes for all the patients with breast cancer, especially those who have advanced breast cancer and not forgetting the issue of drug resistance also poses threat to the successful development of targeted therapy in various subtypes of breast cancer. Unfortunately no targeted drug has been approved for the most aggressive subtype triple negative breast cancer.

Triple Negative Breast Cancer, Breast Cancer, Metastatic Breast Cancer, HER-2, Antibodies

"Current Therapeutic Targets for Breast Cancer Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org), ISSN:2349-5162, Vol.5, Issue 12, page no.407-418, December 2018, Available :http://www.jetir.org/papers/JETIRDZ06054.pdf

"Current Therapeutic Targets for Breast Cancer Treatment", International Journal of Emerging Technologies and Innovative Research (www.jetir.org | UGC and issn Approved), ISSN:2349-5162, Vol.5, Issue 12, page no. pp407-418, December 2018, Available at : http://www.jetir.org/papers/JETIRDZ06054.pdf